1. PRODUCT OVERVIEW
FOXO4-DRI (FOXO4-Derived Redox Interacting Peptide) is a synthetic peptide derived from the transcription factor FOXO4 transcription factor. It is designed to disrupt the interaction between FOXO4 and p53 protein, a key regulator of cell cycle and apoptosis.
By interfering with the FOXO4–p53 interaction, FOXO4-DRI is used in scientific research to investigate mechanisms of cellular senescence, apoptosis, and stress response pathways. The peptide is commonly applied in studies exploring age-related cellular changes and the role of senescent cells in tissue function.
2. STORAGE & HANDLING PROTOCOL
Long-term Storage: Maintain the lyophilized powder at -20°C (-4°F). Ensure the vial remains sealed and protected from light.
Post-Reconstitution: Reconstitute with sterile diluent. Store the resulting solution at 2–8°C (36–46°F).
Stability: For maximum experimental integrity, utilize the reconstituted product within 30 days. Avoid vigorous mechanical agitation.
3. POTENTIAL RESEARCH APPLICATIONS
Cellular Senescence & Apoptosis: Investigating the mechanisms of programmed cell death and the pathways governing cellular aging.
Tissue Remodeling & Stress Response: Studying the role of senescent cells in tissue structural changes and responses to physiological stress.
Senolytic Research Models: Evaluating the selective removal of senescent cells and their impact on senescence-associated signaling pathways.
FOXO4–p53 Cellular Regulation: Investigating the specific interactions between FOXO4 and p53 proteins in the context of cellular health and regulation.
4. REGULATORY DISCLAIMER
NOTICE: This product is supplied strictly FOR LABORATORY RESEARCH and development purposes. It is NOT FOR HUMAN CONSUMPTION, therapeutic, or diagnostic use. This material must be handled by qualified scientific professionals in a controlled environment.
5. REFERENCES
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
https://www.cell.com/cell/fulltext/S0092-8674(17)30246-5 - Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells from In Vitro Expanded Human Chondrocytes
https://pubmed.ncbi.nlm.nih.gov/33996787/ - FOXO4-DRI regulates endothelial cell senescence via the p53 pathway
https://www.frontiersin.org/articles/10.3389/fbioe.2025.1729166/full - FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of p53 phosphorylation
https://www.nature.com/articles/s42003-025-07738-0 - The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
https://www.nature.com/articles/s41467-025-60844-9 - Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides
https://www.sciencedirect.com/science/article/pii/S2352396421004394 - FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
https://www.aging-us.com/article/102682/text - FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype
https://www.sciencedirect.com/science/article/pii/S0531556524001645 - Eliminating Senescent Cells Can Promote Pulmonary Vascular Disease (senolytics context)
https://pubmed.ncbi.nlm.nih.gov/36515093/
Reviews
There are no reviews yet.